ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 317 for:    "drug abuse" | Recruiting, Not yet recruiting, Available Studies

Influence of Medication on Functional Connectivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03612713
Recruitment Status : Recruiting
First Posted : August 2, 2018
Last Update Posted : November 2, 2018
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals

Condition or disease Intervention/treatment Phase
Prescription Drug Abuse (Not Dependent) Drug: Oxycodone Medication First Drug: Placebo First Early Phase 1

Detailed Description:
This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals (N=40, 20 male, 20 female). The objective of this research is to develop an understanding of factors that may influence individual variability on resting state functional connectivity in response to low-dose opioid administration with the longer term aim of understanding addictions vulnerability. Specifically, the proposed pilot research will explore the effects of single dose of oxycodone (15mg) on resting state functional connectivity and other common neuroimaging measures (e.g., diffusion MRI, structural MRI).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: Influence of Medication on Functional Connectivity
Actual Study Start Date : October 30, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Oxycodone Medication First
one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
Drug: Oxycodone Medication First
Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
Other Name: Oxycodone

Placebo Comparator: Placebo First
one hour before fMRI scan participants will be given a single dose placebo.
Drug: Placebo First
Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Other Name: placebo




Primary Outcome Measures :
  1. Change in functional connectivity following oxycodone administration [ Time Frame: Change in functional connectivity from initial fMRI scan to follow-up MRI scan, up to 4 weeks. ]
    Functional connectivity is measured by functional magnetic resonance imagery (fMRI). Change in functional connectivity between placebo and oxycodone fMRI scans will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. males or females, ages 18-30
  2. for women of a child-bearing age, acceptable birth control methods or a negative pregnancy test prior to MRI scanning
  3. ability to provide written, informed consent
  4. eligibility and willingness to participate in fMRI scanning and to receive oxycodone
  5. normal weight, as indicated by a body mass index (BMI) between 18.5 to 25

Exclusion Criteria:

  1. current DSM-5 Axis I disorder
  2. any psychotropic medication or medication known to interfere with metabolism of opioids
  3. medical contraindication to participate in study activities (acute low-dose opioid admin) as determined by study physician
  4. known family history (first-degree relative) of opioid-use disorder or alcohol-use disorder
  5. not eligible for MRI scanning
  6. positive drug screen
  7. recent (past 6 months) medical or non-medical opioid-use
  8. current or previous chronic pain disorder
  9. significant lifetime use of prescription opioids (>7 days of consecutive medical use or nonmedical use on more than 5 occasions)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03612713


Contacts
Contact: Caitlin Sharp, BA (203) 974-7356 caitlin.sharp@yale.edu

Locations
United States, Connecticut
Magnetic Resonance Research Center at The Anlyan Center Yale School of Medicine Recruiting
New Haven, Connecticut, United States, 06511
Principal Investigator: Sarah Yip, PhD         
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Sarah Yip, PhD Yale University

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT03612713     History of Changes
Other Study ID Numbers: 20000 20857
1R21DA045969-01 ( U.S. NIH Grant/Contract )
First Posted: August 2, 2018    Key Record Dates
Last Update Posted: November 2, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Oxycodone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents